Javascript must be enabled to continue!
Clinical Characterization and Mutation Analysis of 13 Iranian Ataxia-Telangiectasia Patients: Introducing Three Novel Mutations
View through CrossRef
Abstract
Background: Ataxia Telangiectasia (AT) is a rare autosomal recessive neurodegenerative disease caused by mutations in the ATM gene. The gene is on chromosome 11q22-23 and codes for the protein kinase ATM, which plays an essential role in DNA damage repair. The classic neurological signs of AT include progressive cerebellar ataxia, oculomotor abnormalities, movement disorders, and cognitive dysfunction. The condition presents with multisystem involvement, leading to immunodeficiency‚ cancer predisposition, oculocutaneous telangiectasia‚ and elevated serum alpha-fetoprotein levels. In this study, we review the clinical characteristics of 13 AT patients, 3 of whom displayed novel mutations.
Method : Thirteen patients with ataxia-telangiectasia from 10 unrelated families were referred to Immunology, Asthma and Allergy Research Institute, Tehran, Iran. After clinical confirmation, blood samples were collected from the patients and their parents. Genetic analysis for 8 patients was conducted using whole-exome sequencing (WES); in the other 3 patients, polymerase chain reaction (PCR) was used, followed by sequencing. The mutations found via WES were confirmed by Sanger sequencing.
Results: We identified 11 different mutations in ATMgene. Two patients had mutations as compound heterozygous, while 9 other patients were homozygous for the mutations. Among these, 3 likely pathogenic mutations (ie, c.4864G>T, c.2639-1G>A, and c.7940_7970delTTCCAGCAGACCAGCCAATTACTAAACTTAA) have not been reported. All parents showed a heterozygous state.
Conclusion: Our study highlights the significance of next-generation sequencing techniques in identifying novel ATMmutations in AT patients. Although all reported AT mutations reside in one gene, the absence of a mutation hotspot for this gene necessitates the use of next-generation sequencing techniques. Specifically, we identified 3 mutations that have not been reported previously, emphasizing the importance of continued research in this area. This study provides new insights into the genetic underpinnings of AT and underscores the potential clinical implications of identifying novel mutations. Further research in this area can help improve diagnosis and inform potential treatments for AT.
Springer Science and Business Media LLC
Mohsen Badalzadeh
Maryam Soleimani Bavani
Zahra Alizadeh
Milad Mirmoghtadaei
Leila Shakerian
Seiamak Bahram
Anne Molitor
Raphael Carapito
Leila Moradi
Anahita Razaghian
Raheleh Assari
Masoud Movahedi
Mansoureh Shariat
Massoud Houshmand
Laleh Habibi
Amir Ali Hamidieh
Mahmoud Reza Ashrafi
Mohammad Reza Fazlollahi
Zahra Pourpak
Title: Clinical Characterization and Mutation Analysis of 13 Iranian Ataxia-Telangiectasia Patients: Introducing Three Novel Mutations
Description:
Abstract
Background: Ataxia Telangiectasia (AT) is a rare autosomal recessive neurodegenerative disease caused by mutations in the ATM gene.
The gene is on chromosome 11q22-23 and codes for the protein kinase ATM, which plays an essential role in DNA damage repair.
The classic neurological signs of AT include progressive cerebellar ataxia, oculomotor abnormalities, movement disorders, and cognitive dysfunction.
The condition presents with multisystem involvement, leading to immunodeficiency‚ cancer predisposition, oculocutaneous telangiectasia‚ and elevated serum alpha-fetoprotein levels.
In this study, we review the clinical characteristics of 13 AT patients, 3 of whom displayed novel mutations.
Method : Thirteen patients with ataxia-telangiectasia from 10 unrelated families were referred to Immunology, Asthma and Allergy Research Institute, Tehran, Iran.
After clinical confirmation, blood samples were collected from the patients and their parents.
Genetic analysis for 8 patients was conducted using whole-exome sequencing (WES); in the other 3 patients, polymerase chain reaction (PCR) was used, followed by sequencing.
The mutations found via WES were confirmed by Sanger sequencing.
Results: We identified 11 different mutations in ATMgene.
Two patients had mutations as compound heterozygous, while 9 other patients were homozygous for the mutations.
Among these, 3 likely pathogenic mutations (ie, c.
4864G>T, c.
2639-1G>A, and c.
7940_7970delTTCCAGCAGACCAGCCAATTACTAAACTTAA) have not been reported.
All parents showed a heterozygous state.
Conclusion: Our study highlights the significance of next-generation sequencing techniques in identifying novel ATMmutations in AT patients.
Although all reported AT mutations reside in one gene, the absence of a mutation hotspot for this gene necessitates the use of next-generation sequencing techniques.
Specifically, we identified 3 mutations that have not been reported previously, emphasizing the importance of continued research in this area.
This study provides new insights into the genetic underpinnings of AT and underscores the potential clinical implications of identifying novel mutations.
Further research in this area can help improve diagnosis and inform potential treatments for AT.
Related Results
Functional parameter measurements in children with ataxia telangiectasia
Functional parameter measurements in children with ataxia telangiectasia
AimTo collect preliminary functional data on ataxia telangiectasia and create a disease specific scale: the Ataxia Telangiectasia Functional Scale (ATFS).MethodRetrospective inform...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Analysis of Molecular Minimal Residual Disease in Patients with Acute Leukemia during Complete Remission
Analysis of Molecular Minimal Residual Disease in Patients with Acute Leukemia during Complete Remission
Abstract
Introduction: Acute leukemia is a group of clonal heterogeneous diseases with high recurrence rate. The monitoring of minimal residual disease (MRD) after t...
Profile of Calreticulin (CALR) Somatic Mutations in a Cohort of Pakistani Patients with Myeloproliferative Neoplasms
Profile of Calreticulin (CALR) Somatic Mutations in a Cohort of Pakistani Patients with Myeloproliferative Neoplasms
Abstract
Introduction:
Calreticulin (CALR) is a calcium binding multifunctional protein encoded by the CALR gene, whose job is to bind to mis-folded p...
Patient with ataxia telangiectasia undergoing elective staging laparoscopy: a case report and literature review
Patient with ataxia telangiectasia undergoing elective staging laparoscopy: a case report and literature review
Ataxia telangiectasia is a rare autosomal recessive condition which develops due to a mutation in the ataxia telangiectasia mutated gene (ATM gene). As a result of this mutation, t...
High Resolution Melt Analysis for Rapid and Cost-Effective Screening of TP53 Mutations in Patients with Myeloid Malignancies
High Resolution Melt Analysis for Rapid and Cost-Effective Screening of TP53 Mutations in Patients with Myeloid Malignancies
Abstract
Background
Recent reports have highlighted an adverse impact of TP53 mutations on the prognosis of patients with myeloid malignancies. TP53 m...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Clinical and Biological Implications of CUX1 Mutations in Myeloid Neoplasms
Clinical and Biological Implications of CUX1 Mutations in Myeloid Neoplasms
Abstract
Recurrent somatic mutations of CUX1 are described in myeloid neoplasms. CUX1 is located at chromosome 7q22.1; -7/del(7q) involving CUX1 locus are common abn...

